IL302132A - Use of anti-pro/latent myostatin antibody to treat spinal muscle wasting - Google Patents

Use of anti-pro/latent myostatin antibody to treat spinal muscle wasting

Info

Publication number
IL302132A
IL302132A IL302132A IL30213223A IL302132A IL 302132 A IL302132 A IL 302132A IL 302132 A IL302132 A IL 302132A IL 30213223 A IL30213223 A IL 30213223A IL 302132 A IL302132 A IL 302132A
Authority
IL
Israel
Prior art keywords
patient
sma
apitegromab
therapy
smn
Prior art date
Application number
IL302132A
Other languages
English (en)
Hebrew (he)
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of IL302132A publication Critical patent/IL302132A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL302132A 2020-10-26 2021-10-25 Use of anti-pro/latent myostatin antibody to treat spinal muscle wasting IL302132A (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202063105850P 2020-10-26 2020-10-26
US202063106172P 2020-10-27 2020-10-27
US202163200955P 2021-04-05 2021-04-05
US202163201157P 2021-04-15 2021-04-15
US202163202317P 2021-06-06 2021-06-06
US202163202372P 2021-06-08 2021-06-08
US202163202900P 2021-06-29 2021-06-29
US202163260725P 2021-08-30 2021-08-30
US202163261398P 2021-09-20 2021-09-20
PCT/US2021/056517 WO2022093724A1 (en) 2020-10-26 2021-10-25 Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy

Publications (1)

Publication Number Publication Date
IL302132A true IL302132A (en) 2023-06-01

Family

ID=78622120

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302132A IL302132A (en) 2020-10-26 2021-10-25 Use of anti-pro/latent myostatin antibody to treat spinal muscle wasting

Country Status (13)

Country Link
US (1) US20240002490A1 (https=)
EP (2) EP4729069A1 (https=)
JP (1) JP2023549455A (https=)
KR (1) KR20230095998A (https=)
CN (1) CN116390756A (https=)
AU (1) AU2021369471A1 (https=)
CA (1) CA3193909A1 (https=)
ES (1) ES3058087T3 (https=)
IL (1) IL302132A (https=)
MX (1) MX2023004763A (https=)
PL (1) PL4232151T3 (https=)
TW (1) TW202233234A (https=)
WO (1) WO2022093724A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
DK4518970T3 (da) 2022-05-04 2026-04-07 Scholar Rock Inc Anvendelse af myostatinhæmmer til behandling af spinal muskelatrofi
IL321628A (en) 2022-12-22 2025-08-01 Scholar Rock Inc Selective and potent inhibitory antibodies for myostatin activation
WO2026076383A1 (en) 2024-10-06 2026-04-09 Scholar Rock, Inc. Use of myostatin inhibitor for treating spinal muscular atrophy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044063A1 (en) 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies
AU2008239606A1 (en) 2007-04-12 2008-10-23 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
AU2017283546C1 (en) 2016-06-13 2020-11-19 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies

Also Published As

Publication number Publication date
EP4232151B1 (en) 2025-10-22
MX2023004763A (es) 2023-05-09
CN116390756A (zh) 2023-07-04
ES3058087T3 (en) 2026-03-06
PL4232151T3 (pl) 2026-02-23
AU2021369471A1 (en) 2023-06-15
EP4232151A1 (en) 2023-08-30
TW202233234A (zh) 2022-09-01
AU2021369471A9 (en) 2024-02-08
JP2023549455A (ja) 2023-11-27
CA3193909A1 (en) 2022-05-05
US20240002490A1 (en) 2024-01-04
KR20230095998A (ko) 2023-06-29
WO2022093724A1 (en) 2022-05-05
EP4729069A1 (en) 2026-04-22

Similar Documents

Publication Publication Date Title
IL302132A (en) Use of anti-pro/latent myostatin antibody to treat spinal muscle wasting
AU2020210134B2 (en) Use of myostatin inhibitors and combination therapies
Arnone et al. Diagnostic and therapeutic guidelines for plaque psoriasis-Brazilian Society of Dermatology
US20250326827A1 (en) Use of myostatin inhibitor for treating spinal muscular atrophy
US20240358704A1 (en) Combined administration
EA051098B1 (ru) Применение антитела к промиостатину/латентному миостатину для лечения спинальной мышечной атрофии
WO2026076383A1 (en) Use of myostatin inhibitor for treating spinal muscular atrophy
TW202436330A (zh) 類升糖素胜肽-2(glp-2)類似物及其用於治療短腸症候群(sbs)之醫藥用途
HK40097101A (en) Use of myostatin inhibitors and combination therapies
HK40043422A (en) Use of myostatin inhibitors and combination therapies
Mason Sites of CGRP action in light aversive behavior: implications for migraine
Mancano New drugs of 2012, part 2
HK1260302B (en) Use of myostatin inhibitors and combination therapies
HK1260302A1 (en) Use of myostatin inhibitors and combination therapies